topic

384 Single-cell transcriptomics, proteomics and in vitro cytotoxicity of allogeneic cryopreserved natural killer cell therapy GTA002 identify potent effector signatures
Monica Raimo, Amanda van Vliet, Denise Vodegel, Daniëlle Steenmans, Adil Duru, Anna-Maria Georgoudaki, Jan Spanholtz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A433; DOI: 10.1136/jitc-2023-SITC2023.0384
385 Selection of CD8+CD103+CD31- tumor infiltrating lymphocytes (TIL) from bulk cultures enriches tumor-specific reactivity in a patient-agnostic manner
Nivedita Ratnam, Frank Lowery, Hyunmi Halas, Stephanie Goff, Steven A Rosenberg

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A434; DOI: 10.1136/jitc-2023-SITC2023.0385
386 Sheltering telomeres from oxidative damage in therapeutic T cells protects against tumor-induced immune dysfunction
Dayana Rivadeneira, Sanjana Thosar, William Gunn, Victoria Dean, Konstantinos Lontos, Marcel Bruchez, Patricia Opresko, Greg Delgoffe

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A435; DOI: 10.1136/jitc-2023-SITC2023.0386
388 A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combination with a PD1–41BB armoring and enhancement costimulatory switch receptor
Dolores Schendel, Giulia Longinotti, Mario Catarinella, Melanie Salvermoser, Julia Bittmann, Kirsty Crame, Kathrin Davari

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A436; DOI: 10.1136/jitc-2023-SITC2023.0388
389 Engineered microenvironment converters (EM-C): macrophages expressing synthetic cytokine receptors reverse immunosuppressive signals in solid tumors
Chris Sloas, Yuhao Huangfu, Silvia Beghi, Rehman Qureshi, Michael Ball, Daniel Blumenthal, Thomas Condamine, Michael Klichinsky, Yumi Ohtani

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A437; DOI: 10.1136/jitc-2023-SITC2023.0389
390 Discovery of MAGE-A1-specific TCR-T cell therapy candidates to expand multiplex therapy of solid tumors
Jenny Tadros, Nancy Nabilsi, Mollie Jurewicz, Akshat Sharma, Kenneth L Jahan, Nicolas Gaspar, Kimberly M Cirelli, Teagan Parsons, Shazad A Khokhar, Shubhangi Kamalia, Sveta Padmanabhan, Badr Kiaf, Ribhu Nayar, Victor Ospina, Alok Das Mahopatra, Tary Traore, Antoine J Boudot, Livio Dukaj, Jin He, Ryan E Kritzer, Alexander Cristofaro, Chandan K Pavuluri, Emily Miga, Qikai Xu, Yifan Wang, Cagan Gurer, Gavin MacBeath

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A438; DOI: 10.1136/jitc-2023-SITC2023.0390
391 Advancing adoptive T cell therapy against AML through the development of CD40L-dual costimulatory receptors
Ryma Toumi, Edison Chiu, Aitong Ruan, Sofia Nguyen, Simonne Guennette, Cody Clayhold, Aayushi Soni, Shannon Oda

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A439; DOI: 10.1136/jitc-2023-SITC2023.0391
392 Engineering T cells to catalyze endogenous anticancer immunity
Ryma Toumi, Simonne Guenette, Edison Chiu, Aitong Ruan, Shannon Oda

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A440; DOI: 10.1136/jitc-2023-SITC2023.0392
393 Rejuvenation of tumor-infiltrating lymphocytes (TIL) through partial reprogramming
Takuya Maeda, Yin Huang, Jessica Fioravanti, Naritaka Tamaoki, Burak Kutlu, Yasuhiro Yamazaki, Kriti Bahl, Biao Wang, Zheng Zhong, Shobha Potluri, Gary Lee, Nicholas Restifo, Raul Vizcardo

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A441; DOI: 10.1136/jitc-2023-SITC2023.0393
394 High-affinity PRAME TCRs synergize with tailored CD8 co-receptor and switch receptors to generate potential best-in-class PRAME-targeting TCR-T therapy
Lia Walcher, Lorenz Knackstedt, Friederike Knipping, Paul Najm, Paul Zschimmer, Panagiota A Sotiropoulou, Elisa Kieback, Marleen van Loenen, Mikhail Steklov, Lucia Poncette

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A442; DOI: 10.1136/jitc-2023-SITC2023.0394

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages